Fiasp® Versus NovoRapid® in Children With Type 1 Diabetes on MiniMed 640G Pump With Sensor
Status:
Unknown status
Trial end date:
2020-04-15
Target enrollment:
Participant gender:
Summary
This is an exploratory, single-center, open label, randomized, complete cross-over trial
comparing safety and efficacy of Fiasp® versus NovoRapid® when used in the Medtronic MiniMed
640G system in pediatric subjects with Type 1 Diabetes Mellitus
Phase:
Phase 4
Details
Lead Sponsor:
Aristotle University Of Thessaloniki
Treatments:
Insulin Aspart Insulin degludec, insulin aspart drug combination Insulin, Long-Acting